{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:12:49Z","timestamp":1789913569455,"version":"4.0.1"},"reference-count":124,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2018,10,16]]},"abstract":"<jats:p>Type II diabetes (T2D) has been identified as a major risk factor for the development of Alzheimer\u2019s disease (AD). Interestingly, both AD and T2D have similar characteristics including amyloid peptide aggregation, decreased metabolism, and increased oxidative stress and inflammation. Despite their prevalence, therapies for these diseases are limited. To date, most therapies for AD have targeted amyloid-\u03b2 or tau. Unfortunately, most of these clinical trials have been largely unsuccessful, creating a crucial need for novel therapies. A number of studies have shown that metabolic hormone therapies are effective at ameliorating high blood glucose levels in diabetics as well as improving cognitive function in AD and mild cognitive impairment patients. Pramlintide, a synthetic analogue of the pancreatic hormone amylin, has been developed and used for years now as a treatment for both type I diabetes and T2D due to the loss of \u03b2-islet cells responsible for producing amylin. Importantly, recent data demonstrates its potential therapeutic role for AD as well. This review aims at addressing parallels between T2D and AD at a pathological and functional level, focusing on amylin signaling as a key, overlapping mediator in both diseases. The potential therapeutic use of this hormone to treat AD will also be explored from a mechanistic viewpoint.<\/jats:p>","DOI":"10.3233\/jad-180433","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T07:23:24Z","timestamp":1538205804000},"page":"11-23","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Neuroprotective Effects of Amylin Analogues on Alzheimer\u2019s Disease Pathogenesis and Cognition"],"prefix":"10.1177","volume":"66","author":[{"given":"John","family":"Grizzanti","sequence":"first","affiliation":[{"name":"School of Biomedical Sciences, Kent State University, Kent, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Corrigan","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Kent State University, Kent, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Casadesus","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, Kent State University, Kent, OH, USA"},{"name":"Department of Biological Sciences, Kent State University, Kent, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,9,26]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.03.001"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828726f5"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.1937"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03830.x"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70088-3"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.2174\/1872214811307020009"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.15.3.318"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-5441-0_5"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009106"},{"key":"e_1_3_1_11_2","first-page":"1","article-title":"Deaths: Final data for 2012","volume":"63","author":"Murphy SL","year":"2015","unstructured":"MurphySL, KochanekKD, XuJ, HeronM (2015) Deaths: Final data for 2012. Natl Vital Stat Rep 63, 1\u2013117.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afs165"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106668"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt269"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.52.1.1"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.02.009"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.06.010"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000306313.89165.ef"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38446.466238.E0"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.2174\/156720507780362047"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31821d69b8"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70112-5"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2005.00704.x"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2006.00842.x"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.8.1467"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1997.03550160069041"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60630-3"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(04)00707-0"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004060050101"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2014.11.016"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050067"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02251132"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2005.01.008"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2005-7107"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59903"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi020314u"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.19.14077"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3028-12.2012"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-016-9684-x"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2008.05.006"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05482"},{"key":"e_1_3_1_42_2","first-page":"245","article-title":"Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells","volume":"135","author":"Johnson K","year":"1989","unstructured":"JohnsonK, O'BrienT, JordanK, WestermarkP (1989) Impaired glucose tolerance is associated with increased islet amyloid polypeptide (IAPP) immunoreactivity in pancreatic beta cells. Am J Pathol 135, 245.","journal-title":"Am J Pathol"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198908243210806"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1169-6"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1249"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-100795"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0196-9781(90)90044-6"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-64-1-190"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.04859.x"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.2174\/156720508785908919"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph6072055"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(96)00629-6"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1177\/153537029922200306"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(08)60991-6"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410320706"},{"key":"e_1_3_1_56_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1994.74.1.139"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2015.09.005"},{"key":"e_1_3_1_58_2","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2007.1754"},{"key":"e_1_3_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2007.12.002"},{"key":"e_1_3_1_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04907.x"},{"key":"e_1_3_1_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601253"},{"key":"e_1_3_1_62_2","first-page":"282","article-title":"Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients","volume":"48","author":"Anello M","year":"2005","unstructured":"AnelloM, LupiR, SpampinatoD, PiroS, MasiniM, BoggiU, Del PratoS, RabuazzoA, PurrelloF, MarchettiP (2005) Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Dia-betologia 48, 282\u2013289.","journal-title":"Dia-betologia"},{"key":"e_1_3_1_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.05603-11"},{"key":"e_1_3_1_64_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708354105"},{"key":"e_1_3_1_65_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2000.00308.x"},{"key":"e_1_3_1_66_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.6.1989"},{"key":"e_1_3_1_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1255-x"},{"key":"e_1_3_1_68_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.18.9866"},{"key":"e_1_3_1_69_2","first-page":"133","article-title":"Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease","volume":"59","author":"Albers DS","year":"2000","unstructured":"AlbersDS, BealMF (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 59, 133\u201354.","journal-title":"J Neural Transm Suppl"},{"key":"e_1_3_1_70_2","doi-asserted-by":"publisher","DOI":"10.3892\/br.2016.630"},{"key":"e_1_3_1_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2014.03.002"},{"key":"e_1_3_1_72_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/105828"},{"key":"e_1_3_1_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-010-0438-z"},{"key":"e_1_3_1_74_2","first-page":"181","article-title":"Inflammation in Alzheimer's disease: Amyloid-\u00df oligomers trigger innate immunity defence via patternrecognitionreceptors","volume":"87","author":"Salminen A","year":"2009","unstructured":"SalminenA, OjalaJ, KauppinenA, KaarnirantaK, SuuronenT (2009) Inflammation in Alzheimer's disease: Amyloid-\u00df oligomers trigger innate immunity defence via patternrecognitionreceptors. ProgNeurobiol 87,181\u2013194.","journal-title":"ProgNeurobiol"},{"key":"e_1_3_1_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00496.x"},{"key":"e_1_3_1_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3916"},{"key":"e_1_3_1_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.07.008"},{"key":"e_1_3_1_78_2","doi-asserted-by":"publisher","DOI":"10.1186\/gm452"},{"key":"e_1_3_1_79_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_666_14"},{"key":"e_1_3_1_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01268.x"},{"key":"e_1_3_1_81_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1082889"},{"key":"e_1_3_1_82_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvq239"},{"key":"e_1_3_1_83_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0702"},{"key":"e_1_3_1_84_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1935"},{"key":"e_1_3_1_85_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0369-6"},{"key":"e_1_3_1_86_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.43.100901.140248"},{"key":"e_1_3_1_87_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006170200"},{"key":"e_1_3_1_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(01)01876-X"},{"key":"e_1_3_1_89_2","first-page":"224","article-title":"Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer's disease","volume":"35","author":"Wang X","year":"2014","unstructured":"WangX, YuS, GaoS-J, HuJ-P, WangY, LiuH-X (2014) Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer's disease. Neuroendocrinol Lett 35, 224\u2013229.","journal-title":"Neuroendocrinol Lett"},{"key":"e_1_3_1_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2008.10.014"},{"key":"e_1_3_1_91_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-7703com"},{"key":"e_1_3_1_92_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200317010-00003"},{"key":"e_1_3_1_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(97)90170-0"},{"key":"e_1_3_1_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1054-3589(05)52006-4"},{"key":"e_1_3_1_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01319.x"},{"key":"e_1_3_1_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(98)00269-1"},{"key":"e_1_3_1_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(97)00231-3"},{"key":"e_1_3_1_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(97)00198-8"},{"key":"e_1_3_1_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2007.06.011"},{"key":"e_1_3_1_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(99)00335-6"},{"key":"e_1_3_1_101_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pu.13.050192.002243"},{"key":"e_1_3_1_102_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00380.2011"},{"key":"e_1_3_1_103_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.331181"},{"key":"e_1_3_1_104_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0230450100"},{"key":"e_1_3_1_105_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04147.x"},{"key":"e_1_3_1_106_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23956"},{"key":"e_1_3_1_107_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160047"},{"key":"e_1_3_1_108_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2013.00042"},{"key":"e_1_3_1_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.11.022"},{"key":"e_1_3_1_110_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01337.x"},{"key":"e_1_3_1_111_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784"},{"key":"e_1_3_1_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2013.10.076"},{"key":"e_1_3_1_113_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160677"},{"key":"e_1_3_1_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.17"},{"key":"e_1_3_1_115_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.03.030"},{"key":"e_1_3_1_116_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1285191"},{"key":"e_1_3_1_117_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0042"},{"key":"e_1_3_1_118_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0589"},{"key":"e_1_3_1_119_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253537"},{"key":"e_1_3_1_120_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.04.005"},{"key":"e_1_3_1_121_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00186"},{"key":"e_1_3_1_122_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2013-1658"},{"key":"e_1_3_1_123_2","first-page":"216","article-title":"Amylin at the interface between metabolic and neurodegenerative disorders","volume":"9","author":"Lutz TA","year":"2015","unstructured":"LutzTA, MeyerU (2015) Amylin at the interface between metabolic and neurodegenerative disorders. Front Neu-rosci 9, 216.","journal-title":"Front Neu-rosci"},{"key":"e_1_3_1_124_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-140210"},{"key":"e_1_3_1_125_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088063"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-180433","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-180433","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-180433","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:08:08Z","timestamp":1777370888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-180433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,26]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,10,16]]}},"alternative-id":["10.3233\/JAD-180433"],"URL":"https:\/\/doi.org\/10.3233\/jad-180433","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,26]]}}}